Xiaoling Ou

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology · 2020 · 413 citations · Full text

Medicine, Oncology, Pharmacology +15

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i> -Amplified Non–Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn et al. · Cancer Discovery · 2022 · 154 citations · Full text

Medicine, Oncology, Pharmacology +17

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

Myung‐Ju Ahn, Byoung Chul Cho, Xiaoling Ou et al. · Journal of Thoracic Oncology · 2022 · 85 citations · Full text

Medicine, Oncology, Pharmacology +13

Prognostic factors for vision outcome after surgical repair of open globe injuries

Rupesh Agrawal, Girish Rao, Rishikesh Naigaonkar et al. · Indian Journal of Ophthalmology · 2011 · 81 citations · Full text

Medicine, Ophthalmology, Surgery +13

Intravitreal Ganciclovir Maintenance Injection for Cytomegalovirus Retinitis: Efficacy of a Low-Volume, Intermediate-Dose Regimen

Stephen C. Teoh, Xiaoling Ou, Tock Han Lim · Ophthalmology · 2011 · 55 citations

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +14